DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
1 Department of Endocrinology and Diabetology, University Medical Center Maribor, Maribor, Slovenia 2 Faculty of Medicine, University of Maribor, Maribor, Slovenia Introduction: Basal insulin with ...
DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...
Shares of medical device company DexCom (NASDAQ:DXCM) jumped 3.7% in the afternoon session after it rebounded from a steep sell-off that was triggered by its long-term revenue growth outlook. The ...
Oct 30 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...
People with Type 1 diabetes are estimated to make up to 180 more decisions a day than someone without the disease, according to a study from Stanford University. Each meal, workout, or night’s sleep ...
Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...
Numerous comments on a Facebook group called “Dexcom G7 – Issues and Complaints” has brought to light a problem that users are referring to as “goose necking.” MD+DI learned more about this issue – ...
Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...
At the 61st annual European Association for the Study of Diabetes Conference (EASD) this week in Vienna, Austria, glucose monitoring company Dexcom introduced its new offering, the Dexcom Smart Basal, ...
A new over-the-counter product cleared by the FDA combines a continuous glucose monitor (CGM) with an artificial intelligence (AI)-based app to assist users in weight management. The Signos Glucose ...
Ladies and gentlemen, welcome to the DexCom Second Quarter 2025 Earnings Release Conference Call. My name is Abby, and I'll be your conference operator today. [Operator Instructions] As a reminder, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback